search
Back to results

Clinical Investigation of Wysa

Primary Purpose

Mental Health Issue, Anxiety, Depressive Symptoms

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Wysa AI chatbot mental health app
Sponsored by
University of Plymouth
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mental Health Issue focused on measuring Artificial Intelligence, Mental Health, Telemedicine, Conversational Agent

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Willing and able to provide informed consent;
  • Aged 18 years or older;
  • Ability to speak English to a secondary school standard;
  • Own a mobile device capable of supporting Wysa;
  • A valid email address;
  • Referred or self-referred to proceed through the standard IAPT care pathway.

Exclusion Criteria:

  • Patients ineligible for the standard IAPT care pathway;
  • Patients with with previous and current known major mental illness such as psychosis, severe depression, any comorbid neurological or neuro-psychiatric condition such as epilepsy;
  • Patients with suicidal ideation;
  • Patients scoring > 15 points on PHQ 9;
  • Patients scoring > GAD - 7
  • Patients with significant cognitive disorders;
  • Patients with noted neurodevelopmental conditions such as autism or ADHD;
  • Patients previously diagnosed with a personality disorder;
  • Patients who been under the care of CMHT or a specialised mental health services in the last 2 years;
  • Patients who failed IAPT previously;
  • Patients with referrals for specialist presentations of pre-existing, diagnosed conditions requiring a specialised assessment beyond the standard clinical pathway;
  • Incapable of self-consent;
  • In a dependent/unequal relationship with the research or care teams or any PPI representatives.

Sites / Locations

  • University of Plymouth
  • Central North West London NHSRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Wysa AI chatbot mental health app

Waitlist control

Arm Description

Wysa is a guided self-help and triaging tool delivered to patients via an app or widget. It uses Natural Language Processing to understand individuals' written inputs but not to generate responses. Wysa makes use of a wide range of clinically underpinned modules whilst gamification, clinical outcome measures and AI promotes engagement, improving efficacy and triage and reducing the cost of scale.

The intervention will be compared against a waitlist group. This comparator was selected to compare Wysa to the current standard of care for patients waiting for standard IAPT assessment and treatment.

Outcomes

Primary Outcome Measures

Depression severity
Score on the PHQ-9, total scores range from 0 to 27 (higher scores indicated more severe depression)

Secondary Outcome Measures

Anxiety severity
Score on the GAD-7, total scores range from 0 to 21 (higher scores indicated more severe anxiety)
Crisis identification
Number of users identified by the app for escalation of care compared to the number of patients in the control group who access A&E or out-of-hours services while waiting for treatment
Uptake rates
Uptake rates of participants randomised into intervention group
Dropout rates
Dropout rates of participants who are randomised into intervention group and start using the app
App usage data
Frequency and duration of app use
Engagement
Qualitative feedback from semi-structured interviews about engagement with the app
Patient perceptions of acceptability
Qualitative feedback from semi-structured interviews about the acceptability of the app
Self-reported acceptability through the app
Automated review questions periodically requested during general use of the tool
General health state
Assessed using the EQ-5D-5L, total scores ranging from 5 to 125 (higher scores indicate more severe health problems)
Impact of health on everyday life
Assessed using the Short Form 12 (SF-12) health survey, total scores ranging from 0 to 100 (higher scores indicate better physical and mental functioning)
Cost-analysis
Assessed using compiled cost data relating to health and social care service use, medication and treatment use, Wysa's implementation, and patients' personal payments or related productivity losses

Full Information

First Posted
September 1, 2022
Last Updated
March 23, 2023
Sponsor
University of Plymouth
Collaborators
Institute of Cancer Research, United Kingdom, Imperial College London, University of Warwick, University of Oxford
search

1. Study Identification

Unique Protocol Identification Number
NCT05533190
Brief Title
Clinical Investigation of Wysa
Official Title
Real World Testing of an Artificial Intelligence-enabled App as an Early Intervention and Support Tool in the Mental Health Referral Care Pathway
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 13, 2022 (Actual)
Primary Completion Date
October 31, 2023 (Anticipated)
Study Completion Date
October 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Plymouth
Collaborators
Institute of Cancer Research, United Kingdom, Imperial College London, University of Warwick, University of Oxford

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Mental health concerns are a large burden for individuals, healthcare systems, and the economy. Over a million people are referred to UK mental health services each year, but more than half only receive one session of workbook-based support. Many others have to wait over 12 weeks for assessment and treatment. Wysa is a digital health app with over 3 million users that uses an artificial intelligence (AI) chatbot and a series of self-care exercises to provide mental health support and to help people develop strategies to manage their mental health and improve their resilience. This project aims to examine the impact of using Wysa on patients' symptoms of anxiety and depression during the referral process for standard UK mental health services. Patients will be given access to Wysa at the point of referral to the Improving Access to Psychological Therapies (IAPT) programme and can begin to explore the self-support tools, while they are on the waitlist for assessment and treatment. The investigators will gather a group of patients and members of the public to contribute to the recruitment of patients for the study, the methods we use to evaluate Wysa, and to provide insights on how best to share the results of our study with the general public. The investigators will use the standard IAPT measures of anxiety and depression to look at the effect of using Wysa patients' mental well-being. These questionnaires will be provided through the app and the results will be compared with a waitlist control group. The investigators will examine whether Wysa can identify people who are experiencing severe mental health difficulties so that they can be provided with additional support. Users' levels of engagement with Wysa will be assessed and some participants will be randomly selected to do an interview so the investigators can get a better understanding of what people liked and disliked about using the app and why. Finally, the investigators will be evaluating the cost-effectiveness of Wysa compared with usual care. The investigators expect that the study will show that Wysa helps reduce symptoms of anxiety and depression in people who are on the waiting list for IAPT. If the study shows this positive impact, this will provide evidence to support the use of Wysa to improve the accessibility of mental health support in clinical pathways. The investigators will be publishing the results of our study in academic journals as well as in more generally accessible platforms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mental Health Issue, Anxiety, Depressive Symptoms
Keywords
Artificial Intelligence, Mental Health, Telemedicine, Conversational Agent

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants will be randomly allocated to the intervention condition or a standard care waitlist control condition.
Masking
None (Open Label)
Masking Description
Due to the nature of the intervention, no blinding of participants will be possible in the study, as all participants will know whether or not they are using the app. Clinical treatment teams will also not be blinded as they will know through the electronic patient record if a participant has received the intervention. The evaluation team will be blinded to treatment using the randomisation algorithm.
Allocation
Randomized
Enrollment
480 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Wysa AI chatbot mental health app
Arm Type
Experimental
Arm Description
Wysa is a guided self-help and triaging tool delivered to patients via an app or widget. It uses Natural Language Processing to understand individuals' written inputs but not to generate responses. Wysa makes use of a wide range of clinically underpinned modules whilst gamification, clinical outcome measures and AI promotes engagement, improving efficacy and triage and reducing the cost of scale.
Arm Title
Waitlist control
Arm Type
No Intervention
Arm Description
The intervention will be compared against a waitlist group. This comparator was selected to compare Wysa to the current standard of care for patients waiting for standard IAPT assessment and treatment.
Intervention Type
Device
Intervention Name(s)
Wysa AI chatbot mental health app
Intervention Description
Wysa is a guided self-help and triaging tool delivered to patients via an app. It includes a chatbot and makes use of a wide range of clinically underpinned modules to provide mental health support.
Primary Outcome Measure Information:
Title
Depression severity
Description
Score on the PHQ-9, total scores range from 0 to 27 (higher scores indicated more severe depression)
Time Frame
3 months post-randomisation
Secondary Outcome Measure Information:
Title
Anxiety severity
Description
Score on the GAD-7, total scores range from 0 to 21 (higher scores indicated more severe anxiety)
Time Frame
3 months post-randomisation
Title
Crisis identification
Description
Number of users identified by the app for escalation of care compared to the number of patients in the control group who access A&E or out-of-hours services while waiting for treatment
Time Frame
Over 9 month intervention period
Title
Uptake rates
Description
Uptake rates of participants randomised into intervention group
Time Frame
Over 9 month intervention period
Title
Dropout rates
Description
Dropout rates of participants who are randomised into intervention group and start using the app
Time Frame
Over 9 month intervention period
Title
App usage data
Description
Frequency and duration of app use
Time Frame
Over 9 month intervention period
Title
Engagement
Description
Qualitative feedback from semi-structured interviews about engagement with the app
Time Frame
Over 9 month intervention period
Title
Patient perceptions of acceptability
Description
Qualitative feedback from semi-structured interviews about the acceptability of the app
Time Frame
Over 9 month intervention period
Title
Self-reported acceptability through the app
Description
Automated review questions periodically requested during general use of the tool
Time Frame
Over 9 month intervention period
Title
General health state
Description
Assessed using the EQ-5D-5L, total scores ranging from 5 to 125 (higher scores indicate more severe health problems)
Time Frame
Measured at baseline and 3 months post-randomisation
Title
Impact of health on everyday life
Description
Assessed using the Short Form 12 (SF-12) health survey, total scores ranging from 0 to 100 (higher scores indicate better physical and mental functioning)
Time Frame
Measured at baseline and 3 months post-randomisation
Title
Cost-analysis
Description
Assessed using compiled cost data relating to health and social care service use, medication and treatment use, Wysa's implementation, and patients' personal payments or related productivity losses
Time Frame
Over 9 month intervention period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Willing and able to provide informed consent; Aged 18 years or older; Ability to speak English to a secondary school standard; Own a mobile device capable of supporting Wysa; A valid email address; Referred or self-referred to proceed through the standard IAPT care pathway. Exclusion Criteria: Patients ineligible for the standard IAPT care pathway; Patients with previous and current known major mental illness such as Schizophrenia, severe depression, any co-morbid neurological or neuro-psychiatric condition such as epilepsy; Patients with current psychosis or a history of psychotic symptoms within the last 6 months; Patients with suicidal ideation; Patients scoring > 15 points on PHQ 9; Patients scoring > 15 points on GAD-7; Patients with significant cognitive disorders; Patients with noted neurodevelopmental conditions such as autism or ADHD; Patients previously diagnosed with a personality disorder; Patients who been under the care of CMHT or a specialised mental health services in the last 2 years; Patients who failed IAPT previously; Patients with referrals for specialist presentations of pre-existing, diagnosed conditions requiring a specialised assessment beyond the standard clinical pathway; Incapable of self-consent; In a dependent/unequal relationship with the research or care teams or any PPI representatives.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Edward Meinert, PhD
Phone
01752600600
Email
edward.meinert@plymouth.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Madison Milne-Ives, MSc
Phone
01752600600
Email
madison.milne-ives@plymouth.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rohit Shankar, FRCPsych
Organizational Affiliation
University of Plymouth
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Plymouth
City
Plymouth
State/Province
Devon
ZIP/Postal Code
PL4 6DN
Country
United Kingdom
Individual Site Status
Active, not recruiting
Facility Name
Central North West London NHS
City
London
ZIP/Postal Code
NW1 3AX
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alina Paik, BSc

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Only the Academic CIs and their research staff will have access to research data.

Learn more about this trial

Clinical Investigation of Wysa

We'll reach out to this number within 24 hrs